News & AnalysisExscientia pulls in $225m Series DExscientia, a clinical stage pharmatech company, has raised $225 million in Series D funding.ByIris Dorbian28 April 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs